Evercore ISI Group Upgrades Prothena Corp to Outperform, Announces $14 Price Target Benzinga_NewsdeskTue, 19 Nov 2019 06:53:40 -0500
Prothena Corp 13D Shows EcoR1 Capital Holds 23.6% Stake In Co.
Shares of several gene therapy companies are trading higher potentially in sympathy with Nightstar Therapeutics after the company announced it would be acquired by Biogen for $25.50 per share in cash.
Cantor Fitzgerald Assumes Prothena Corp at Overweight
Market Data 
Markets 
AI
